# Topical treatment of diabetic foot ulcers using a novel quercetin-loaded hyaluosome gel nanoformulation

**Authors:** Mohamed S. Amer, Khalid A. El-Nesr, Fatma I. Abo El-Ela, Mohamed I. Zanaty

PMC · DOI: 10.1038/s41598-026-37537-4 · Scientific Reports · 2026-02-17

## TL;DR

A new gel containing quercetin in hyaluosome nanoparticles shows promise for treating diabetic foot ulcers by reducing inflammation and promoting healing.

## Contribution

A novel quercetin-loaded hyaluosome gel nanoformulation is developed and tested for diabetic foot ulcer treatment.

## Key findings

- The nanoformulation achieved 88.1% entrapment efficiency and showed favorable physicochemical properties.
- QCN-HS reduced pro-inflammatory cytokines and increased antioxidant levels in DFU models.
- The gel promoted extracellular matrix remodeling and suppressed NF-κB expression in skin tissue.

## Abstract

Diabetic foot ulcers (DFUs) are among the most severe and debilitating complications of diabetes mellitus, often progressing to limb amputation due to persistent, non-healing lesions. Because of the multifactorial pathogenesis of DFUs, there is a pressing demand for novel drug delivery approaches capable of enhancing treatment effectiveness. This study aimed to enhance topical drug delivery for DFU management through the formulation and optimization of a Quercetin-loaded hyaluosome gel (QCN-HS). The nanoformulation was prepared and characterized, followed by in vitro and in vivo evaluations. The optimized QCN-HS demonstrated an entrapment efficiency of 88.1%, a mean particle size of 122.42 nm, and a zeta potential of − 24 mV. Morphological assessment by transmission electron microscopy revealed a uniform cuboidal-to-rounded square architecture without aggregation, further validated by FTIR spectroscopy. QCN-HS significantly reduced the expression of pro-inflammatory cytokines (TGF-β, TNF-α, IL-17, and IL-6) and lowered MPO activity, while markedly increasing GST and GSH levels. Moreover, QCN-HS downregulated ADAMTS-5 and MMP-13 while upregulating TIMP-3, findings corroborated by scratch assay and IC50 data, confirming effective regulation of extracellular matrix turnover. Histological and immunohistochemical analyses further demonstrated significant suppression of NF-κB expression in skin tissue. The quercetin-loaded hyaluosome gel, with favorable physicochemical properties and high entrapment efficiency, showed strong therapeutic potential for DFU treatment. Both in vitro and in vivo results underscore its ability to attenuate inflammation, enhance antioxidant defenses, and promote extracellular matrix remodeling; these outcomes strengthen the rationale for QCN-HS as an effective targeted treatment for DFUs.

## Linked entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040], TNF (tumor necrosis factor) [NCBI Gene 7124], IL17A (interleukin 17A) [NCBI Gene 3605], IL6 (interleukin 6) [NCBI Gene 3569], ADAMTS5 (ADAM metallopeptidase with thrombospondin type 1 motif 5) [NCBI Gene 11096], MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322], TIMP3 (TIMP metallopeptidase inhibitor 3) [NCBI Gene 7078], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Chemicals:** quercetin (PubChem CID 5280343), GST (PubChem CID 5288476), GSH (PubChem CID 124886)
- **Diseases:** diabetes mellitus (MONDO:0005015)

## Full-text entities

- **Diseases:** diabetic foot ulcers (MESH:D017719)
- **Chemicals:** quercetin (MESH:D011794)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12921244/full.md

## Figures

15 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12921244/full.md

## References

12 references — full list in the complete paper: https://tomesphere.com/paper/PMC12921244/full.md

---
Source: https://tomesphere.com/paper/PMC12921244